Heinrich Schmidt
Heinrich Schmidt has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Angelika Enders
Dr. von Hauner Children's Hospital University of Munich, Munich, Germany
1 shared publicationBirgit Kammer
Dr. von Hauner Children's Hospital University of Munich, Munich, Germany
1 shared publicationImma Rost
Center for Human Genetics and Laboratory Medicine, Martinsried, Germany
1 shared publicationJoachim Pohlenz
Children’s Hospital, Johannes Gutenberg University, Mainz, Germany
1 shared publicationMonika Grasser
Dr. von Hauner Children's Hospital University of Munich, Munich, Germany
1 shared publicationNicole Pfarr
Children’s Hospital, Johannes Gutenberg University, Mainz, Germany
1 shared publication
Latest Publications
- 19 February 2009
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 51 (3) , 240-244
Elevated serum triiodothyronine and intellectual and motor disability with paroxysmal dyskinesia caused by a monocarboxylate transporter 8 gene mutation
Monocarboxylate transporter 8 (MCT8 or SLC16A2) is important for the neuronal uptake of triiodothyronine (T3) in its function as a specific and active transporter of thyroid hormones across the cell membrane, thus being essential for human brain development. We report on a German male with Allan–Herndon–Dudley syndrome presenting with severe intellectual and motor disability, paroxysmal dyskinesia combined with truncal muscular hypotonia, and peripheral muscular hypertonia at his current age of 9 years. Additionally, the patient has a lesion in the left putamen region revealed by magnetic resonance imaging and elevated serum T3 levels. The male appeared to have a hemizygous mutation (R271H) in the MCT8 gene that was sequenced directly from genomic DNA and occurred de novo in the maternal germline, as both his mother and his sister were not carriers of the mutation. Ruling out a common polymorphism, 50 normal individuals of the same ethnic background did not harbour the mutation. The identified MCT8 gene mutation (R271H) is very likely to be the genetic cause for neuronal hypothyroidism despite elevated serum T3 levels.
- 19 February 2009
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 51 (3) , 240-244
Elevated serum triiodothyronine and intellectual and motor disability with paroxysmal dyskinesia caused by a monocarboxylate transporter 8 gene mutation
Monocarboxylate transporter 8 (MCT8 or SLC16A2) is important for the neuronal uptake of triiodothyronine (T3) in its function as a specific and active transporter of thyroid hormones across the cell membrane, thus being essential for human brain development. We report on a German male with Allan–Herndon–Dudley syndrome presenting with severe intellectual and motor disability, paroxysmal dyskinesia combined with truncal muscular hypotonia, and peripheral muscular hypertonia at his current age of 9 years. Additionally, the patient has a lesion in the left putamen region revealed by magnetic resonance imaging and elevated serum T3 levels. The male appeared to have a hemizygous mutation (R271H) in the MCT8 gene that was sequenced directly from genomic DNA and occurred de novo in the maternal germline, as both his mother and his sister were not carriers of the mutation. Ruling out a common polymorphism, 50 normal individuals of the same ethnic background did not harbour the mutation. The identified MCT8 gene mutation (R271H) is very likely to be the genetic cause for neuronal hypothyroidism despite elevated serum T3 levels.
- 6 July 2007
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 143A (16) , 1868-1875
Endochondral gigantism: A newly recognized skeletal dysplasia with pre‐ and postnatal overgrowth and endocrine abnormalities
We report on a 3‐year‐old male, born at 34 weeks of gestation, with marked pre‐ and postnatal overgrowth, birth weight of 6,600 g, length of 61 cm, and head circumference of 38.5 cm. A striking phenotype was recorded at birth, which became more evident during the follow‐up period. He had macrobrachycephaly, facial abnormalities, small thoracic cage, long trunk, deformed spine, rhizomelia, large hands and feets, absent subcutaneous fat, small umbilical hernia, inguinal hernias, and large joints with mild contractures. Hypoglycemic episodes and obstructive apnea complicated the neonatal period. During follow‐up, overgrowth continued with a height of 146 cm (+11.65 SDS) and a weight of 39 kg (BMI 18.3 kg/m2) at 3.5 years. Endocrinological work‐up disclosed extremely low levels of growth hormone, insulin‐like growth factors, and insulin. What makes our patient unique is the association of marked prenatal overgrowth; unusual phenotype; skeletal dysplasia caused by accelerated endochondral ossification resulting in cartilage hyperplasia of the skull base and spine, and postnatal gigantism; and complete absence of subcutaneous fat. Other well‐known overgrowth syndromes were excluded. We hypothesize that autocrine/paracrine growth factors could be the cause of excessive endochondral ossification. Alternately, activating mutations in transcription factors involved in both growth and endocrine/metabolic homeostasis could be responsible for this unusual phenotype.
- 6 July 2007
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 143A (16) , 1868-1875
Endochondral gigantism: A newly recognized skeletal dysplasia with pre‐ and postnatal overgrowth and endocrine abnormalities
We report on a 3‐year‐old male, born at 34 weeks of gestation, with marked pre‐ and postnatal overgrowth, birth weight of 6,600 g, length of 61 cm, and head circumference of 38.5 cm. A striking phenotype was recorded at birth, which became more evident during the follow‐up period. He had macrobrachycephaly, facial abnormalities, small thoracic cage, long trunk, deformed spine, rhizomelia, large hands and feets, absent subcutaneous fat, small umbilical hernia, inguinal hernias, and large joints with mild contractures. Hypoglycemic episodes and obstructive apnea complicated the neonatal period. During follow‐up, overgrowth continued with a height of 146 cm (+11.65 SDS) and a weight of 39 kg (BMI 18.3 kg/m2) at 3.5 years. Endocrinological work‐up disclosed extremely low levels of growth hormone, insulin‐like growth factors, and insulin. What makes our patient unique is the association of marked prenatal overgrowth; unusual phenotype; skeletal dysplasia caused by accelerated endochondral ossification resulting in cartilage hyperplasia of the skull base and spine, and postnatal gigantism; and complete absence of subcutaneous fat. Other well‐known overgrowth syndromes were excluded. We hypothesize that autocrine/paracrine growth factors could be the cause of excessive endochondral ossification. Alternately, activating mutations in transcription factors involved in both growth and endocrine/metabolic homeostasis could be responsible for this unusual phenotype.